Emcure Pharmaceuticals announced that Poviztra, its co-marketed brand of innovator semaglutide (rDNA origin), will now be available for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2-F3). This follows the Central Drugs Standard Control Organization's (CDSCO) approval of Wegovy for the indication, marking the first and only GLP-1 receptor agonist approved in India for this progressive liver disease.

The approval addresses a significant unmet medical need for patients with MASH, a condition often asymptomatic until advanced stages. MASH develops when excess fat accumulation in the liver leads to chronic inflammation, fibrosis, and progressive liver damage, and is closely linked with obesity, type 2 diabetes, and other metabolic disorders.

Clinical Trial Data

The regulatory approval is supported by results from the global Phase III ESSENCE trial. The study demonstrated that semaglutide achieved resolution of steatohepatitis in 63% of patients and improvement in liver fibrosis in 37% of patients. Additionally, one in three patients achieved both resolution of steatohepatitis and improvement in liver fibrosis.

Strategic Expansion

Poviztra contains innovator semaglutide (rDNA-origin) manufactured and imported from Novo Nordisk's European manufacturing facility. The drug is already established in chronic weight management for persons living with obesity and those overweight with co-morbid conditions such as hypertension, dyslipidemia, and type 2 diabetes. It is also approved for obese patients with established cardiovascular disease and for the management of adolescent obesity in pediatric patients above 12 years.

Satish Mehta, Chief Executive Officer & Managing Director of Emcure Pharmaceuticals Limited, stated that the approval marks an important milestone for patients living with a serious and often underdiagnosed liver disease. He emphasized that the company is committed to bringing globally validated, innovative therapies to India and plans to work closely with healthcare professionals to improve awareness and encourage earlier diagnosis.

Through its subsidiary Zuventus Healthcare's strong gastroenterology and hepatology portfolio, Emcure aims to expand MASH awareness, diagnosis, and treatment access across the country.

Emcure Pharmaceuticals has announced it will host an earnings conference call to discuss its unaudited financial results for the quarter ended June 30, 2026. The call is scheduled for Thursday, August 6, 2026, at 4:00 PM IST and will cover the company's standalone and consolidated performance for Q1 FY27.

The management team will conduct the session via Zoom Webinar, beginning with brief remarks followed by a question-and-answer session for analysts and investors. The disclosure was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Participants are required to register in advance, and the company has advised attendees to join the webinar 10 minutes prior to the scheduled start time to ensure a smooth connection.

Conference Call Details

The key details of the scheduled earnings call are outlined below:

Post-Call Disclosures

Following the conclusion of the earnings call, Emcure Pharmaceuticals will make an audio recording available before the next trading day or within 24 hours from the end of the call, whichever is earlier. A full transcript of the proceedings will be published within five working days. Both the audio recording and the transcript will be accessible on the company's official website, www.emcure.com , under the Investors section. Institutional investors with queries may contact Saurabh Paliwal via email at investor.relations@emcure.com .